RET-targeting drug study for advanced cancers with RET changes
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (as defined by your local region’s rules).
- Your tumor must have a RET gene abnormality (found on biopsy tissue or a blood test).
- You have advanced or metastatic solid cancer, and at least some measurable tumor (or non-measurable disease the study allows).
- Your general fitness (“ECOG performance”) must be 0–1 for Phase 1 and 0–2 for Phase 2.
- Your liver, kidney, and blood counts must be adequate based on blood tests.
- If you have brain or covering-of-the-brain (“leptomeningeal”) metastases, you must be symptom-free and stable on medicines for at least 7 days (or already treated and stable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests lunbotinib, a new medicine that targets a specific lung-cancer change called RET. It aims to see how well it works and how safe it is for adults with advanced RET-altered non-small cell lung cancer.
This Phase 1 trial tests how safe TRE-515 is, what dose can be used, and how the drug moves through the body, including using PET scans. It’s for adults with advanced solid cancers that have stopped responding to standard treatment.
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests an investigational drug, SNH-118110, for people with advanced solid tumors that have a specific genetic change called RET. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests an experimental drug called HS-10365 for people with advanced or metastatic non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug aims to block the growth of cancer cells with this mutation.
Hear when a new RET-altered Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.